Japanese Abilify growth helps Otsuka ride currency-hit quarter
This article was originally published in Scrip
Executive Summary
Currency effects, European cost-saving measures and indirect generic competition weighed on the global sales of Otsuka Holdings' top product, the atypical antipsychotic Abilify (aripiprazole), in the first quarter, although line extensions helped boost its performance in Japan.